Eingeschlossene Patienten: 23.771 (Stand 01. Oktober 2025) | |
---|---|
Amgevita® (Adalimumab) | 268 |
Benepali® (Etanercept) | 1305 |
Cimzia® (Certolizumab) | 1062 |
Enbrel® (Etanercept) | 2879 |
Erelzi® (Etanercept) | 623 |
Flixabi® (Infliximab) | 10 |
Hukyndra® (Adalimumab) | 18 |
Hulio® (Adalimumab) | 309 |
Humira® (Adalimumab) | 2912 |
Hyrimoz® (Adalimumab) | 285 |
Idacio® (Adalimumab) | 73 |
Imraldi® (Adalimumab) | 248 |
Inflectra™ (Infliximab) | 16 |
Jyseleca® (Filgotinib) | 187 |
Kevzara® (Sarilumab) | 243 |
Kineret® (Anakinra) | 89 |
MabThera® (Rituximab) | 1459 |
Nepexto® (Etanercept) | 106 |
Olumiant® (Baricitinib) | 564 |
Orencia® (Abatacept) | 1000 |
Remicade® (Infliximab) | 762 |
Remsima® (Infliximab) | 27 |
Rinvoq® (Upadacitinib) | 354 |
Rixathon® (Rituximab) | 20 |
RoActemra® (Tocilizumab) | 1381 |
Ruxience® (Rituximab) | 1 |
Simponi® (Golimumab) | 481 |
Truxima® (Rituximab) | 8 |
Tyenne® (Tocilizumab) | 73 |
Xeljanz® (Tofacitinib) | 404 |
Yuflyma® (Adalimumab) | 73 |
Zessly® (Infliximab) | 2 |
Kontrollen | 6529 |